title: Allogeneic versus autologous bone marrow transplantation versus chemotherapy for treatment of acute myeloid leukemia in first complete remission (BGM 84 and BGMT 87 studies). The BGMT Group.
authors.forename: J
authors.initials: J
authors.lastname: Reiffers
authors.forename: A M
authors.initials: AM
authors.lastname: Stoppa
authors.forename: F
authors.initials: F
authors.lastname: Rigal-Huguet
authors.forename: M
authors.initials: M
authors.lastname: Michallet
authors.forename: G
authors.initials: G
authors.lastname: Marit
authors.forename: J A
authors.initials: JA
authors.lastname: Gastaut
authors.forename: M
authors.initials: M
authors.lastname: Attal
authors.forename: B
authors.initials: B
authors.lastname: Corront
authors.forename: A
authors.initials: A
authors.lastname: Broustet
authors.forename: D
authors.initials: D
authors.lastname: Hollard
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D008875:Middle Aged; D011446:Prospective Studies; D012074:Remission Induction; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous
chemical_list: D003561:Cytarabine; D003630:Daunorubicin